文献速递姑息放疗与转移瘤

骨转移与非骨病灶姑息放疗疼痛缓解的前瞻性比较研究

Pain response to palliative radiotherapy in bone metastases vs. non-bone lesions: Prospective study.
PubMed 文献 · Radiother Oncol · 2025-04-18

本研究基于ICPRE标准比较骨转移与非骨病灶姑息放疗的疼痛缓解。前瞻性队列纳入500例患者867个可评估病灶,符合标准678个病灶中骨转移541个(80%)、非骨病灶137个(20%)。两组12周内疼痛缓解率无显著差异(57% vs 62%,P=0.33),非骨病灶组中增加照射剂量可能影响疼痛缓解,提示潜在剂量依赖性。

要点

  • 骨转移与非骨病灶姑息放疗12周疼痛缓解率无显著差异(57% vs 62%,P=0.33)。
  • 非骨病灶组中位生存期较短(4.9个月 vs 6.3个月,P=0.017)。
  • 骨转移组再照射与阿片类药物使用对疼痛缓解有负面影响。

核心结论

  • 姑息放疗对疼痛性非骨病灶有效,疼痛缓解可能呈剂量依赖性。

研究设计与样本

  • 两队列研究,使用2021年8月至2023年9月前瞻性队列数据,纳入500例患者867个登记病灶。

主要发现

  • 符合标准的678个病灶中,骨转移组541个(80%),非骨病灶组137个(20%),包括原发肿瘤、淋巴结转移等。
  • 两组12周内疼痛缓解率无显著差异(57% vs 62%,P=0.33),调整协变量后结果一致。
  • 非骨病灶组中位生存期较短(4.9个月 vs 6.3个月,P=0.017),更常采用分次照射(85% vs 67%,P<0.001)。
  • 骨转移组中再照射与阿片类药物使用与疼痛缓解负面相关;非骨病灶组中增加照射剂量可能影响疼痛缓解。

关键数值与推荐

  • 采用ICPRE标准在预设时间点2、4、12、24、36、52周评估疼痛缓解。
  • 89%的病灶接受常规放疗:单次8 Gy、20 Gy/5次或30 Gy/10次。
  • 阿片类药物使用率67%,再照射率22%,两组间无差异。

临床怎么用

  • 姑息放疗可用于疼痛性非骨病灶的疼痛缓解。
  • 非骨病灶的疼痛缓解可能呈剂量依赖性,需未来随机对照试验确定最佳剂量。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study compared the pain response to palliative radiotherapy for bone metastases and non-bone lesions based on the International Consensus on Palliative Radiotherapy Effectiveness (ICPRE) criteria. METHODS: This two-cohort study used data from a prospective cohort of 867 registered lesions from 500 patients conducted between August 2021 and September 2023. Pain responses were assessed using the ICPRE criteria at prespecified timings of 2, 4, 12, 24, 36, and 52 weeks. The primary outcome was the pain response rate within 12 weeks, comparing two groups of patients with bone and non-bone lesions. A multivariate logistic regression analysis was conducted to adjust for confounding covariates based on opioid use, irradiation history, performance status, NRS, primary disease, and radiation dose. RESULTS: Among 678 lesions from 440 patients who met the criteria, 541 (80 %) and 137 (20 %) were in the bone and non-bone cohort, including primary tumors, lymph node metastases, and others. The mean age was 63 years, and 45 % were female. Treatment included conventional radiotherapy of a single 8 Gy dose, 20 Gy in 5 fractions, and 30 Gy in 10 fractions, used in 89 % of lesions. While opioid use (67 %) and re-irradiation rates (22 %) were not different between cohorts, the non-bone cohort had shorter median survival (4.9 months vs. 6.3 months, P = 0.017) and more frequently fractionated irradiation (85 % vs. 67 %, P < 0.001). No differences were observed in pain response rates between the two groups (57 % vs. 62 %, P = 0.33), which remained consistent after adjusting covariates. Re-irradiation and opioid were associated with negative impacts on pain response in the bone cohort. In contrast, the increased irradiation dose was identified as potentially affecting the non-bone cohort. CONCLUSIONS: This study suggested palliative radiotherapy is effective for painful non-bone lesions and potential dose-dependency for pain response, highlighting the need for future randomized controlled trials to determine the optimal radiation dose.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Koide Y, Noguchi M, Shindo Y, et al. Pain response to palliative radiotherapy in bone metastases vs. non-bone lesions: Prospective study. Radiother Oncol. 2025. PMID: 40254168. doi:10.1016/j.radonc.2025.110901

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。